What is Waldenstrom’s Macroglobulinemia?
Waldenstrom’s Macroglobulinemia is treated with 1 medication in our database, including Imbruvica. 1 of these has manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Pharmacyclics. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Waldenstrom’s Macroglobulinemia treatment below.
- Inheritance
- Multifactorial
- Caused by a mix of several genes and environmental factors
- Age of Onset
- Late onset
- Begins later in life, typically after age 50
Treatments
0 FDA-approved · 1 other trackedSource: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly
Other tracked therapies (1)
Medications tracked in our therapeutics database that are not FDA-approved for Waldenstrom’s Macroglobulinemia via a labelled indication. May include investigational, off-label, or supportive therapies. Always verify with a clinician before use.
Imbruvica
* Patient Copay Amount: As little as $0 per prescription * Maximum Annual Benefit Limit: Not Publicly Available * Core Eligibility Restrictions: Available to patients with commercial insurance coverag
Clinical Trials
View all trials with filters →Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest
No actively recruiting trials found for Waldenstrom’s Macroglobulinemia at this time.
New trials open frequently. Follow this disease to get notified.
Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)
Specialty unconfirmed
University Medical Center Utrecht
Specialty unconfirmed
Memorial Sloan Kettering Cancer Center
Specialty unconfirmed
Centre Hospitalier Universitaire (CHU)
Specialty unconfirmed
University Hospital Ulm
Specialty unconfirmed
Fondazione IRCCS Policlinico San Matteo
Specialty unconfirmed
Karolinska Institute
Specialty unconfirmed
linical Therapeutics
Specialty unconfirmed
Dana Farber Cancer Institute; and Harvard Medical School
Specialty unconfirmed
University Hospital of Salamanca
Specialty unconfirmed
University Hospital Amiens- Picardie
Specialty unconfirmed
Plasma Cell Diseases Group Colorado Blood Cancer Institute
Specialty unconfirmed
University Hospital of Salamanca
Specialty unconfirmed
National Clinical Research Center for Blood Diseases
Specialty unconfirmed
Clínica Universidad de Navarra
Specialty unconfirmed
Département d'Hématologie Hôpital Pitié-Salpêtrière AP-HP
Treatment Centers
8 centersSource: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months
Children's Hospital Colorado Rare Disease Program ↗
Children's Hospital Colorado
📍 Aurora, CO
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDBoston Children's Hospital Rare Disease Program ↗
Boston Children's Hospital
📍 Boston, MA
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
🏨 Children'sAnn & Robert H. Lurie Children's Hospital Genetics ↗
Lurie Children's Hospital
📍 Chicago, IL
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDCincinnati Children's Hospital Medical Center ↗
Cincinnati Children's
📍 Cincinnati, OH
👤 Boston Children's Hospital Rare Disease Program
🏨 Children'sNationwide Children's Hospital Rare Disease Center ↗
Nationwide Children's Hospital
📍 Columbus, OH
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
Travel Grants
6 grantsNORD/IWMF Patient Assistance Program
National Organization for Rare Disorders (NORD), International Waldenstrom's Macroglobulinemia Foundation (IWMF)
IMBRUVICA By Your Side
myBeOne Support Program
NORD Rare Disease Educational Support Program / Travel & Lodging Assistance Program
National Organization for Rare Disorders (NORD), International Waldenstrom's Macroglobulinemia Foundation (IWMF)
Community
No community posts yet. Be the first to share your experience with Waldenstrom’s Macroglobulinemia.
Start the conversation →Latest news about Waldenstrom’s Macroglobulinemia
Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC
No recent news articles for Waldenstrom’s Macroglobulinemia.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Waldenstrom’s Macroglobulinemia
What is Waldenstrom’s Macroglobulinemia?
Waldenstrom’s Macroglobulinemia is treated with 1 medication in our database, including Imbruvica. 1 of these has manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Pharmacyclics. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Waldenstrom’s Macroglobulinemia treatment below.
How is Waldenstrom’s Macroglobulinemia inherited?
Waldenstrom’s Macroglobulinemia follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Waldenstrom’s Macroglobulinemia typically begin?
Typical onset of Waldenstrom’s Macroglobulinemia is late onset. Age of onset can vary across affected individuals.
Which specialists treat Waldenstrom’s Macroglobulinemia?
15 specialists and care centers treating Waldenstrom’s Macroglobulinemia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Waldenstrom’s Macroglobulinemia?
1 FDA-approved treatment are currently tracked on UniteRare for Waldenstrom’s Macroglobulinemia. See the treatments and support programs sections for copay assistance, eligibility, and contact details.
Frequently asked questions about Waldenstrom’s Macroglobulinemia
Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.
What is Waldenstrom’s Macroglobulinemia?
Waldenstrom’s Macroglobulinemia is a rare disease catalogued in international rare-disease ontologies. It is typically inherited as multifactorial. Age of onset is generally late onset. For verified primary sources, see the UniteRare Waldenstrom’s Macroglobulinemia page.
How is Waldenstrom’s Macroglobulinemia inherited?
Waldenstrom’s Macroglobulinemia follows multifactorial inheritance. Genetic counseling is recommended for affected families to understand recurrence risk in offspring and the likelihood of unaffected siblings being carriers. Variants in the underlying gene(s) may be identified via clinical genetic testing.
Are there FDA-approved treatments for Waldenstrom’s Macroglobulinemia?
Yes — UniteRare tracks 1 FDA-approved treatment with indications relevant to Waldenstrom’s Macroglobulinemia. Each entry includes prescribing information, orphan-drug-designation status where applicable, and the FDA application number for verification.
Are there clinical trials for Waldenstrom’s Macroglobulinemia?
Active clinical trials for Waldenstrom’s Macroglobulinemia are tracked daily from ClinicalTrials.gov. Trial availability changes frequently; check the UniteRare trial listings for the current count and recruitment status. Sponsors of rare-disease research often welcome inquiries even when a trial is not actively recruiting at a given moment.
How do I find a specialist for Waldenstrom’s Macroglobulinemia?
UniteRare lists 15 verified clinicians with documented expertise in Waldenstrom’s Macroglobulinemia, sourced from ClinicalTrials.gov principal-investigator records, PubMed publication histories, and the NPPES NPI registry. Filter by state or browse our state-specific specialist pages for nearby options.
See full Waldenstrom’s Macroglobulinemia page for complete clinical details, sources, and verified-specialist listings.
Cite this page
Select a citation format above to view and copy.